



Recombinant SARS-CoV-2 NSP8 [Avi] (DAGC355)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) NSP8 Protein (YP_009725304.1) (Ala1-Gln198) was expressed with a AVI tag at the C-terminus.
Species	SARS-CoV-2
Purity	> 90 % as determined by SDS-PAGE.
Conjugate	Avi
Applications	ELISA
Predicted N terminal	Gly
Molecular Weight	The recombinant SARS-CoV-2 (2019-nCoV) NSP8 consists of 220 amino acids and predicts a molecular mass of 24.17 kDa.
Format	Lyophilized
Size	100 μg, 1 mg
Buffer	Lyophilized from sterile 20mM Tris 500mM NaCl pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Preservative	None
Storage	Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

BACKGROUND

45-1 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882 Fax: 1-631-938-8221

Introduction NSP8 is a nonstructural protein of coronavirus. NSP8 acts as a primase in RNA synthesis. NSP8 and NSP7 are essential co-factors of NSP12 (the catalytic subunit with RNA-dependent RNA polymerase activity) that can remarkably stimulates RdRp activity. The nsp12-nsp7-nsp8 subcomplex is defined as the minimal core component for mediating coronavirus RNA synthesis. Keywords SARS-CoV-2 NSP8; SARS-CoV-2